Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Effectiveness of Varicella Zoster Immune Globulin Administration within 96 Hours versus more than 96 Hours after Exposure to the Varicella-Zoster Virus

수두 바이러스에 노출 후 96시간 이내와 96시간 이후에 수두 면역 글로불린 투여시 수두 예방 효과에 관한 연구

  • Kim, Sun-Ja (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Byung-Kee (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Yang-Hyun (Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Soo-Jin (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Yae-Jean (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 김선자 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 이병기 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 김양현 (성균관대학교 의과대학 삼성 생명과학 연구소) ;
  • 김수진 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 김예진 (성균관대학교 의과대학 삼성서울병원 소아청소년과)
  • Received : 2014.10.21
  • Accepted : 2014.10.29
  • Published : 2015.08.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Varicella Zoster Immune Globulin (VZIG) is available in Korea for post-exposure prophylaxis of the Varicella-zoster virus (VZV) in high-risk patients. In July 2013, the United States Centers for Disease Control and Prevention (US CDC) recommended extending the time for administration of VariZIG$^{(R)}$ from within 96 hours up to 10 days after VZV exposure. This study was performed to analyze the effectiveness of VZIG prophylaxis between the two groups of patients who received VZIG within 96 hours and more than 96 hours of exposure to varicella. Methods: A retrospective chart review was performed in pediatric patients who received VZIG at Samsung Medical Center, Seoul, Korea from January 2001 to December 2012. Results: A total of 91 patients were identified. Fifty-seven patients were male (62.6%) and the median age was 5.91 years. Thirty-nine patients (42.9%) were exposed to VZV in the hospital. Underlying diseases were solid tumors (41.8%), hematologic malignancies (40.7%), and others (17.5%). Forty-five patients (49.5%) were hematopoietic cell transplant recipients. Seventy-four patients (81.3%) received VZIG within 96 hours after VZV exposure. There was no significant difference in the development of chickenpox between the two groups (2.7% vs. 5.9%, P=0.4664). In 22 seronegative patients, we also observed no significant difference between the groups in terms of the development of chickenpox (6.6% vs. 0%, P=0.667). Conclusions: This study showed that the effectiveness of VZIG for the prevention of chickenpox was comparable between patients who received VZIG within 96 hours and those who received VZIG more than 96 hours after exposure to VZV.

목적: 고위험군 환자에서 수두 바이러스 접촉 후 예방 요법으로 수두 면역 글로불린을 투여한다. 수두 면역 글로불린으로 국내에서는 VZIG, 미국에서는 VariZIG$^{(R)}$을 사용한다. 2013년 7월 미국 질병관리본부에서 수두 바이러스 노출 후 VariZIG$^{(R)}$ 투여를 최대 10일까지로 연장하여도 수두 예방 효과가 있음을 발표하였다. 본 연구에서 저자들은 수두 노출 후 96시간 이내에 VZIG 투여 군과 96시간 이후 투여 군에서 수두 예방 효과를 비교하고자 하였다. 방법: 삼성서울병원에서 2001년 1월부터 2012년 12월 사이에 VZIG이 투여된 환자들을 대상으로 후향적 차트 분석을 통해 평가하였다. 결과: 전체 91명의 환자에서 57명(62.6%)은 남자였고 연령의 중앙값은 5.91세였다. 39명(42.9%)은 병원 내에서 수두 바이러스에 노출되었다. 기저 질환은 고형 종양 41.8%, 혈액 종양 40.7%이었고 그 외 다른 질환이 17.5%이었다. 전체 환자 중에서 45명(49.5%)은 조혈모세포 이식 환자였다. 74명(81.3%)이 수두 바이러스 노출 후 96시간 이내에 VZIG을 투여 받았다. 수두 바이러스 노출 후 96시간 이내에 VZIG이 투여된 군과 96시간 이후에 투여된 군에서 수두 발생은 뚜렷한 차이가 없었다(2.7% vs. 5.9%, P=0.4664). 효소면역분석법 검사에서 수두 항체가 음성인 환자는 22명이었고, 이 환자들에서 수두 바이러스 노출 후 96시간 이내에 VZIG이 투여된 군과 96시간 이후에 투여된 군에서 수두 발생은 뚜렷한 차이가 없었다(6.6% vs. 0%, P=0.667). 결론: 본 연구에 의하면 수두 노출 후 96시간 이전에 VZIG 투여군과 96시간 이후에 VZIG 투여군 사이에 수두 발생을 예방하는데 차이가 없었으나, 향후 더 많은 환자수에서 추가 연구가 필요할 것으로 사료된다.

Keywords

References

  1. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-5.
  2. Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975;56:388-97.
  3. Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis 2008;197 Suppl 2:S200-6. https://doi.org/10.1086/522133
  4. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-40.
  5. Orenstein WA, Heymann DL, Ellis RJ, Rosenberg RL, Nakano J, Halsey NA, et al. Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin. J Pediatr 1981;98:368-73. https://doi.org/10.1016/S0022-3476(81)80697-X
  6. Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep 2013;62:574-6.
  7. Winsnes R. Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. Acta Paediatr Scand 1978;67:77-82.
  8. Evans EB, Pollock TM, Cradock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980;1:354-6.
  9. Enders G ME. Varicella-zoster virus: virology and clinical management. In: Varicella and herpes zoster in pregnancy and the newborn. Cambridge, UK: Cambridge University Press, 2000.
  10. Koren G, Money D, Boucher M, Aoki F, Petric M, Innocencion G, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002;42:267-74. https://doi.org/10.1177/00912700222011283
  11. Pickering LK, Baker CJ, Kimberlin DW, Long SS. Red book 2012:p92, p774-81.
  12. Cameron JC, Allan G, Johnston F, Finn A, Heath PT, Booy R. Severe complications of chickenpox in hospitalised children in the UK and Ireland. Arch Dis Child 2007;92:1062-6. https://doi.org/10.1136/adc.2007.123232
  13. Balfour HH, Jr. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med 1988;85:68-73. https://doi.org/10.1016/0002-9343(88)90366-X
  14. Swingler G. Chickenpox. Clin Evid 2003:755-62.
  15. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996;45:1-36.
  16. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-81.
  17. Roderick M, Finn A, Ramanan AV. Chickenpox in the immunocompromised child. Arch Dis Child 2012;97:587-9. https://doi.org/10.1136/archdischild-2012-301684
  18. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 1987;80:465-72.
  19. Brandt L, Broadbent V. A survey of recommendations given to patients going home after bone marrow transplant. Arch Dis Child 1994;71:529-31. https://doi.org/10.1136/adc.71.6.529
  20. Weinstock DM, Boeckh M, Sepkowitz KA. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006;12:1096-7. https://doi.org/10.1016/j.bbmt.2006.06.005
  21. Bate J, Chisholm J, Heath PT, Breuer J, Skinner R, Manley S, et al. PEPtalk: postexposure prophylaxis against varicella in children with cancer. Arch Dis Child 2011;96:841-5. https://doi.org/10.1136/adc.2010.209650
  22. Weinstock DM, Boeckh M, Boulad F, Eagan JA, Fraser VJ, Henderson DK, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol 2004;25:603-8. https://doi.org/10.1086/502447
  23. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998;17:256-7. https://doi.org/10.1097/00006454-199803000-00020
  24. Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969;280:1191-4. https://doi.org/10.1056/NEJM196905292802201
  25. Brunell PA, Gershon AA, Hughes WT, Riley HD, Jr., Smith J. Prevention of varicella in high risk children: a collaborative study. Pediatrics 1972;50:718-22.
  26. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983;147:737-43. https://doi.org/10.1093/infdis/147.4.737
  27. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006;55:209-10.
  28. FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012;61:212.
  29. Enders G, Bolley I, Miller E, Cradock-Watson J, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. The Lancet 1994;343:1548-51. https://doi.org/10.1016/S0140-6736(94)92943-2